CYTO | Altamira Therapeutics Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4116 - 0.4451
52 Week Range	0.4000 - 17.20
Beta	1.93
Implied Volatility	601.12%
IV Rank	73.14%
Day's Volume	36,336
Average Volume	79,614
Shares Outstanding	3,778,520
Market Cap	1,662,171
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-08-06

Valuation
Profitability
Growth
Health
P/E Ratio	0.24
Forward P/E Ratio	N/A
EPS	1.82
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	10
Country	Bermuda
Website	CYTO

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.

CYTO's peers: APM, ATNF, PYXS, ZURA, EFTR, ELEV, IMMX, ENVB, PALI, CNSP, ZVSA, VECT, AVRO, DARE, DRMA, DRUG, EPIX, GOVX, NBTX, NBY, ORMP, PSTV, PYPD, REVB, TENX, VTGN, VTVT, XBIO, CDIO, CARM

*Chart delayed

Analyzing fundamentals for CYTO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see CYTO Fundamentals page.

Watching at CYTO technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on CYTO Technicals page.